Novel therapeutics to reduce the progression of retinal degenerations

Investigating therapeutics to slow the progression of retinal degenerations

school Student intake
This project is open for Honours, Masters, Doctor of Medicine and Surgery and PhD students.
traffic Project status

Project status

contact_support Contact
Contact name
Associate Professor Riccardo Natoli

Content navigation


In recent years, ophthalmic drugs have enjoyed a relatively high probability of success in progressing from Phase I clinical trials to market, estimated in 2015 at ~30%. This clinical success is driven by good preclinical models, especially for wet AMD. In 2016 we developed a mouse model for mimicking the oxidative stress, inflammation and cell death characteristics of the more prevalent form of AMD – dry AMD. This model has opened up both fundamental science and commercial opportunities to better understand and develop new strategies for combating dry AMD. In the Clear Vision Research Lab we are exploring a number of therapeutic options, developed at ANU and by commercial partners, which include gene-based therapies, non-invasive therapeutics (including the use of low-level laser therapy using red light) and novel compounds. We are actively engaging with commercial partners to help develop strategies to slow the progression of retinal degenerations, by targeting inflammation and oxidative stress processes.


Principal investigator

Associate Director Research
Associate Professor, School of Medicine and Psychology